| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M |
| P698 | PubMed publication ID | 9751088 |
| P50 | author | David T Felson | Q37393431 |
| Michael LaValley | Q37839673 | ||
| P2093 | author name string | Anderson JJ | |
| Wells G | |||
| Lange ML | |||
| P433 | issue | 9 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1564-1570 | |
| P577 | publication date | 1998-09-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? | |
| P478 | volume | 41 |
| Q37133200 | A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis |
| Q87526876 | A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate |
| Q78124689 | ACR 20: clinical or statistical significance? |
| Q34118958 | Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study |
| Q36408155 | Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities |
| Q34108783 | Biologic therapies in rheumatoid arthritis |
| Q78124802 | Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et al |
| Q37270792 | Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis |
| Q34098412 | Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? |
| Q24186209 | Celecoxib for rheumatoid arthritis |
| Q57318857 | Celecoxib for rheumatoid arthritis |
| Q34071257 | Clinical outcome measures in rheumatoid arthritis |
| Q39837952 | Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial |
| Q35553459 | Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis |
| Q43048686 | Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden |
| Q35553458 | Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis |
| Q57169507 | Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice |
| Q50799528 | Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. |
| Q36563395 | Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials |
| Q37144969 | Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. |
| Q24792072 | Efficacy and safety of acupuncture for chronic pain caused by gonarthrosis: a study protocol of an ongoing multi-centre randomised controlled clinical trial [ISRCTN27450856] |
| Q53828369 | Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. |
| Q33622648 | Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement |
| Q35555648 | Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis |
| Q36519316 | Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. |
| Q34553844 | Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study |
| Q50127594 | MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial |
| Q33234551 | Measuring disease activity for rheumatoid arthritis |
| Q35959354 | Meridian-sinew release therapy for the treatment of refractory rheumatoid arthritis. |
| Q36278027 | Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial |
| Q37619717 | Outcome measures in inflammatory rheumatic diseases |
| Q36140811 | Outcome measures in psoriatic arthritis |
| Q33782360 | PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases |
| Q31038425 | Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors |
| Q79603683 | Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone |
| Q35780344 | Pursuit of optimal outcomes in rheumatoid arthritis |
| Q44750988 | Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis |
| Q43052844 | Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis |
| Q36040052 | Science of assessment |
| Q51773490 | Semi-quantitative analysis of rheumatoid finger joint synovitis using power Doppler ultrasonography: when to perform follow-up study after treatment consisting mainly of antitumor necrosis factor alpha agent. |
| Q35760130 | Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol |
| Q77838669 | Targeting interleukin-1 in the treatment of rheumatoid arthritis |
| Q37137011 | The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial. |
| Q64256884 | The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial |
| Q83980148 | Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study |
| Q36633112 | Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study. |
| Q39390356 | What decline in pain intensity is meaningful to patients with acute pain? |
Search more.